Skip to content

Resistance associated substitutions to direct acting antiviral agents in Pegylated interferon plus ribavirin treatment experienced patients with chronic hepatitis C

Resistance associated substitutions to direct acting antiviral agents in Pegylated interferon plus ribavirin treatment experienced patients with chronic hepatitis C

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020845
Enrollment
Unknown
Registered
2019-01-21
Start date
2019-01-17
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Interventions

P/R treatment failure in CHC patients:None

Sponsors

Beijing You'an Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: More than 60 patients failed to receive PR regimen (including non-response and recurrence) in the national "Eleventh Five-Year Plan" major infectious disease hepatitis C special project "Study on the clinical outcome of viral hepatitis C and the mechanism and treatment optimization of refractory viral hepatitis C". In accordance with the CHC diagnostic criteria established in the 2004 Guidelines for the Prevention and Treatment of Hepatitis C; in the compensatory period of liver function; for high viral load (HCV RNA (> 4x105IU/ml) or genotype 1b; without other types of viral hepatitis or HIV infection; non-pregnancy, lactation and other systemic diseases.

Exclusion criteria

Exclusion criteria: 1. cirrhosis of liver; 2. diagnosis or suspected hepatocellular carcinoma; 3. allergic history of IFN, RBV or other components; 4. acute and chronic liver damage caused by other hepatitis viruses (HAV, HCV, HDV, HEV) infection or other causes; 5. alcoholism or drug addicts; 6. autoimmune liver disease, malignant tumors and contraindications of IFN (such as severe cardiopulmonary disease, renal insufficiency, uncontrollable). Asthma or diabetes, unstable thyroid or other serious endocrine diseases, uncontrollable epilepsy, severe mental illness, active pulmonary tuberculosis, psoriasis, etc.

Design outcomes

Primary

MeasureTime frame
RAS;

Countries

China

Contacts

Public ContactShan Ren

Beijing You'an Hospital, Capital Medical University

13811361553@163.com+86 13811361553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026